Search

Your search keyword '"Hohnloser, Stefan H."' showing total 1,791 results
Start Over Author "Hohnloser, Stefan H."

Refine your results

more »

more »

more »

more »

more »
1,791 results on '"Hohnloser, Stefan H."'

2. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA

Author

Lopes, Renato D., Granger, Christopher B., Wojdyla, Daniel M., McIntyre, William F., Alings, Marco, Mani, Thenmozhi, Ramasundarahettige, Chinthanie, Rivard, Lena, Atar, Dan, Birnie, David H., Boriani, Giuseppe, Amit, Guy, Leong-Sit, Peter, Rinne, Claus, Duray, Gabor Z., Gold, Michael R., Hohnloser, Stefan H., Kutyifa, Valentina, Benezet-Mazuecos, Juan, Cosedis Nielsen, Jens, Sticherling, Christian, Benz, Alexander P., Linde, Cecilia, Kautzner, Joseph, Mabo, Philippe, Mairesse, Georges H., Connolly, Stuart J., and Healey, Jeff S.

Published
2024
Full Text
View/download PDF

3. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials

Author

Klug, Didier, Casolla, Barbara, Puy, Laurent, Coffee, Morgane, Kuchcinski, Grégory, Labreuche, Julien, van Nieuwenhuizen, Koen M., Algra, Ale, van Gelder, Isabelle C., Kappelle, L. Jaap, Rinkel, Gabriel J.E., Schutgens, Roger E.G., Khatri, Pooja, Conwit, Robin, Falcone, Guido, Elm, Jordan, Anderson, Craig S., Song, Lili, Pandian, Jeyaraj, Hart, Robert G., Sharma, Mukul, Aref, Hany, Tarhuni, Wadea, Fabregas, Joan Marti, Diener, Hans-Christoph, Endres, Matthias, Lemmens, Robin, Kwon, Sun U., Lee, Byung-Chul, Ameriso, Sebastian, Milling, Truman J., Kasner, Scott E., Mikulik, Robert, Xavier, Denis, Beer, Ronny, Toni, Danilo, Eckstein, Jens, Seiffge, David, Ferro, Jose M., Tsivgoulis, Georgios, Sharma, Sanjib K., Wei-Liou, Chia, Hohnloser, Stefan H., Katsanos, Aristeidis, Bosch, Jackie, Healey, Jeff, Eikelboom, John, Khaw, Alexander, Gladstone, David, Pikula, Aleksandra, Coutts, Shelagh, Smith, Eric E., Butcher, Ken, Field, Thalia, Gioia, Laura, Stapf, Christian, Halse, Omid, Ringleb, Peter, Enzinger, Christian, Sibon, Igor, Montaner, Joan, Caso, Valeria, Heuschmann, Peter, Lip, Gregory Y.H., Haefeli, Walter, Debette, Stefanie, Dennis, Martin S., Wyller, Torgeir Bruun, Rønning, Ole M., Eilertsen, Helle, Ihle-Hansen, Hege, Sandset, Else Charlotte, Pennlert, Johanna, Glader, Eva-Lotta, Kruuse, Christina, Wester, Per, Carlsson, Maria, Forfang, Elisabeth, Al-Shahi Salman, Rustam, Stephen, Jacqueline, Tierney, Jayne F, Lewis, Steff C, Newby, David E, Parry-Jones, Adrian R, White, Philip M, Connolly, Stuart J, Benavente, Oscar R, Dowlatshahi, Dar, Cordonnier, Charlotte, Viscoli, Catherine M, Sheth, Kevin N, Kamel, Hooman, Veltkamp, Roland, Larsen, Kristin T, Hofmeijer, Jeannette, Kerkhoff, Henk, Schreuder, Floris H B M, Shoamanesh, Ashkan, Klijn, Catharina J M, and van der Worp, H Bart

Published
2023
Full Text
View/download PDF

9. Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI

Author

De Caterina, Raffaele, Procopio, Antonio, Lopez Sendon, José-Luis, Raev, Dimitar, Mehta, Shamir R., Opolski, Grzegorz, Oldgren, Jonas, Steg, Philippe Gabriel, Hohnloser, Stefan H., Lip, Gregory Y.H., Kimura, Takeshi, Kleine, Eva, ten Berg, Jurriën M., Bhatt, Deepak L., Miede, Corinna, Nordaby, Matias, and Cannon, Christopher P.

Published
2020
Full Text
View/download PDF

10. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

Author

ten Berg, Jurrien M., Steg, Philippe Gabriel, Bhatt, Deepak L., Hohnloser, Stefan H., de Veer, Anne, Nordaby, Matias, Miede, Corinna, Kimura, Takeshi, Lip, Gregory Y.H., Oldgren, Jonas, and Cannon, Christopher P.

Published
2020
Full Text
View/download PDF

12. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials

Author

Al-Shahi Salman, Rustam, primary, Stephen, Jacqueline, additional, Tierney, Jayne F, additional, Lewis, Steff C, additional, Newby, David E, additional, Parry-Jones, Adrian R, additional, White, Philip M, additional, Connolly, Stuart J, additional, Benavente, Oscar R, additional, Dowlatshahi, Dar, additional, Cordonnier, Charlotte, additional, Viscoli, Catherine M, additional, Sheth, Kevin N, additional, Kamel, Hooman, additional, Veltkamp, Roland, additional, Larsen, Kristin T, additional, Hofmeijer, Jeannette, additional, Kerkhoff, Henk, additional, Schreuder, Floris H B M, additional, Shoamanesh, Ashkan, additional, Klijn, Catharina J M, additional, van der Worp, H Bart, additional, Klug, Didier, additional, Casolla, Barbara, additional, Puy, Laurent, additional, Coffee, Morgane, additional, Kuchcinski, Grégory, additional, Labreuche, Julien, additional, van Nieuwenhuizen, Koen M., additional, Algra, Ale, additional, van Gelder, Isabelle C., additional, Kappelle, L. Jaap, additional, Rinkel, Gabriel J.E., additional, Schutgens, Roger E.G., additional, Khatri, Pooja, additional, Conwit, Robin, additional, Falcone, Guido, additional, Elm, Jordan, additional, Anderson, Craig S., additional, Song, Lili, additional, Pandian, Jeyaraj, additional, Hart, Robert G., additional, Sharma, Mukul, additional, Aref, Hany, additional, Tarhuni, Wadea, additional, Fabregas, Joan Marti, additional, Diener, Hans-Christoph, additional, Endres, Matthias, additional, Lemmens, Robin, additional, Kwon, Sun U., additional, Lee, Byung-Chul, additional, Ameriso, Sebastian, additional, Milling, Truman J., additional, Kasner, Scott E., additional, Mikulik, Robert, additional, Xavier, Denis, additional, Beer, Ronny, additional, Toni, Danilo, additional, Eckstein, Jens, additional, Seiffge, David, additional, Ferro, Jose M., additional, Tsivgoulis, Georgios, additional, Sharma, Sanjib K., additional, Wei-Liou, Chia, additional, Hohnloser, Stefan H., additional, Katsanos, Aristeidis, additional, Bosch, Jackie, additional, Healey, Jeff, additional, Eikelboom, John, additional, Khaw, Alexander, additional, Gladstone, David, additional, Pikula, Aleksandra, additional, Coutts, Shelagh, additional, Smith, Eric E., additional, Butcher, Ken, additional, Field, Thalia, additional, Gioia, Laura, additional, Stapf, Christian, additional, Halse, Omid, additional, Ringleb, Peter, additional, Enzinger, Christian, additional, Sibon, Igor, additional, Montaner, Joan, additional, Caso, Valeria, additional, Heuschmann, Peter, additional, Lip, Gregory Y.H., additional, Haefeli, Walter, additional, Debette, Stefanie, additional, Dennis, Martin S., additional, Wyller, Torgeir Bruun, additional, Rønning, Ole M., additional, Eilertsen, Helle, additional, Ihle-Hansen, Hege, additional, Sandset, Else Charlotte, additional, Pennlert, Johanna, additional, Glader, Eva-Lotta, additional, Kruuse, Christina, additional, Wester, Per, additional, Carlsson, Maria, additional, and Forfang, Elisabeth, additional

Published
2023
Full Text
View/download PDF

16. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P., Hong, Hwanhee, Connolly, Stuart J., Eikelboom, John, Giugliano, Robert P., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Alexander, John H., Cecilia Bahit, M., Benz, Alexander P., Bohula, Erin A., Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, A.A. Fox, Keith, Gencer, Baris, Halperin, Jonathan L., Hijazi, Ziad, Hohnloser, Stefan H., Hua, Kaiyuan, Hylek, Elaine, Toda Kato, Eri, Kuder, Julia, Lopes, Renato D., Mahaffey, Kenneth W., Oldgren, Jonas, Piccini, Jonathan P., Ruff, Christian T., Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B.

Published
2022
Full Text
View/download PDF

17. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Author

Healey, Jeff S., primary, Lopes, Renato D., additional, Granger, Christopher B., additional, Alings, Marco, additional, Rivard, Lena, additional, McIntyre, William F., additional, Atar, Dan, additional, Birnie, David H., additional, Boriani, Giuseppe, additional, Camm, A. John, additional, Conen, David, additional, Erath, Julia W., additional, Gold, Michael R., additional, Hohnloser, Stefan H., additional, Ip, John, additional, Kautzner, Josef, additional, Kutyifa, Valentina, additional, Linde, Cecilia, additional, Mabo, Philippe, additional, Mairesse, Georges, additional, Benezet Mazuecos, Juan, additional, Cosedis Nielsen, Jens, additional, Philippon, Francois, additional, Proietti, Marco, additional, Sticherling, Christian, additional, Wong, Jorge A., additional, Wright, David J., additional, Zarraga, Ignatius G., additional, Coutts, Shelagh B., additional, Kaplan, Andrew, additional, Pombo, Marta, additional, Ayala-Paredes, Felix, additional, Xu, Lizhen, additional, Simek, Kim, additional, Nevills, Sandra, additional, Mian, Rajibul, additional, and Connolly, Stuart J., additional

Published
2023
Full Text
View/download PDF

18. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Author

Benz, Alexander P, Hohnloser, Stefan H, Eikelboom, John W, Carnicelli, Anthony P, Giugliano, Robert P, Granger, Christopher B, Harrington, Josephine, Hijazi, Ziad, Morrow, David A, Patel, Manesh R, Seiffge, David J, Shoamanesh, Ashkan, Wallentin, Lars, Yi, Qilong, and Connolly, Stuart J

Subjects
610 Medizin und Gesundheit, Cardiology and Cardiovascular Medicine
Abstract

Aims The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a stroke event while on oral anticoagulation. Methods and results Individual participant data from five pivotal randomized trials of antithrombotic therapy in AF were used to assess the outcomes of patients with a post-randomization ischemic stroke while on study medication (warfarin, standard-, or lower-dose direct oral anticoagulant regimen) during trial follow-up. The primary outcome was recurrent ischemic stroke after the first post-randomization ischemic stroke. The primary analysis included 1163 patients with a first post-randomization ischemic stroke while on study medication (median age 73 years, 39.3% female, 35.4% history of stroke before trial enrollment). During a median continued follow-up of 337 days, 74 patients had a recurrent ischemic stroke [cumulative incidence at 1 year: 7.0%, 95% confidence interval (CI) 5.2%–8.7%]. The cumulative incidence of mortality at 3 months after stroke was 12.4% (95% CI 10.5%–14.4%). Consistent results for the incidence of recurrent ischemic stroke at 1 year were obtained in an analysis accounting for the competing risk of death (6.2%, 95% CI 4.8%–7.9%) and in a landmark analysis excluding the first 2 weeks after the index stroke and only including patients without permanent study drug discontinuation since then (6.8%, 95% CI 4.6%–8.9%). Conclusion Patients with AF and ischemic stroke while on oral anticoagulation are at increased risk of recurrent ischemic stroke and death. These patients currently have an unmet medical need.

Published
2023

20. Digoxin and Mortality in Patients With Atrial Fibrillation

Author

Lopes, Renato D., Rordorf, Roberto, De Ferrari, Gaetano M., Leonardi, Sergio, Thomas, Laine, Wojdyla, Daniel M., Ridefelt, Peter, Lawrence, John H., De Caterina, Raffaele, Vinereanu, Dragos, Hanna, Michael, Flaker, Greg, Al-Khatib, Sana M., Hohnloser, Stefan H., Alexander, John H., Granger, Christopher B., and Wallentin, Lars

Published
2018
Full Text
View/download PDF

31. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

Author

Berry, Natalia C., Mauri, Laura, Steg, Philippe Gabriel, Bhatt, Deepak L., Hohnloser, Stefan H., Nordaby, Matias, Miede, Corinna, Kimura, Takeshi, Lip, Gregory Y.H., Oldgren, Jonas, ten Berg, Jurriën M., and Cannon, Christopher P.

Published
2020
Full Text
View/download PDF

33. Effect of dronedarone vs. placebo on atrial fibrillation progression : a post hoc analysis from ATHENA trial

Author

Blomström-Lundqvist, Carina, Naccarelli, Gerald, V, McKindley, David S., Bigot, Gregory, Wieloch, Mattias, Hohnloser, Stefan H., Blomström-Lundqvist, Carina, Naccarelli, Gerald, V, McKindley, David S., Bigot, Gregory, Wieloch, Mattias, and Hohnloser, Stefan H.

Abstract

Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo. Methods and results: The burden of AF/AFL was estimated by a modified Rosendaal method using available electrocardiograms (ECG). Cumulative incidence of permanent AF/AFL (defined as >= 6 months of AF/AFL until end of study) or permanent SR (defined as >= 6 months of SR until end of study) were calculated using Kaplan-Meier estimates. A log-rank test was used to assess statistical significance. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were estimated using a Cox model, adjusted for treatment group. Of the 4439 patients included in this analysis, 2208 received dronedarone, and 2231 placebo. Baseline and clinical characteristics were well balanced between groups. Overall, 304 (13.8%) dronedarone-treated patients progressed to permanent AF/AFL compared with 455 (20.4%) treated with placebo (P < 0.0001). Compared with those receiving placebo, patients receiving dronedarone had a lower cumulative incidence of permanent AF/AFL (log-rank P < 0.001; HR: 0.65; 95% CI: 0.56-0.75), a higher cumulative incidence of permanent SR (log-rank P < 0.001; HR: 1.19; 95% CI: 1.09-1.29), and a lower estimated AF/AFL burden over time (P < 0.01 from Day 14 to Month 21). Conclusion: These results suggest that dronedarone could be a useful antiarrhythmic drug for early rhythm control due to less AF/AFL progression and more regression to SR vs. placebo, potentially reflecting reverse remodeling.

Published
2023
Full Text
View/download PDF

34. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Author

Benz, Alexander P., Hohnloser, Stefan H., Eikelboom, John W., Carnicelli, Anthony P., Giugliano, Robert P., Granger, Christopher B., Harrington, Josephine, Hijazi, Ziad, Morrow, David A., Patel, Manesh R., Seiffge, David J., Shoamanesh, Ashkan, Wallentin, Lars, Yi, Qilong, Connolly, Stuart J., Benz, Alexander P., Hohnloser, Stefan H., Eikelboom, John W., Carnicelli, Anthony P., Giugliano, Robert P., Granger, Christopher B., Harrington, Josephine, Hijazi, Ziad, Morrow, David A., Patel, Manesh R., Seiffge, David J., Shoamanesh, Ashkan, Wallentin, Lars, Yi, Qilong, and Connolly, Stuart J.

Abstract

Aims The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a stroke event while on oral anticoagulation. Methods and results Individual participant data from five pivotal randomized trials of antithrombotic therapy in AF were used to assess the outcomes of patients with a post-randomization ischemic stroke while on study medication (warfarin, standard-, or lower-dose direct oral anticoagulant regimen) during trial follow-up. The primary outcome was recurrent ischemic stroke after the first post-randomization ischemic stroke. The primary analysis included 1163 patients with a first post-randomization ischemic stroke while on study medication (median age 73 years, 39.3% female, 35.4% history of stroke before trial enrollment). During a median continued follow-up of 337 days, 74 patients had a recurrent ischemic stroke [cumulative incidence at 1 year: 7.0%, 95% confidence interval (CI) 5.2%-8.7%]. The cumulative incidence of mortality at 3 months after stroke was 12.4% (95% CI 10.5%-14.4%). Consistent results for the incidence of recurrent ischemic stroke at 1 year were obtained in an analysis accounting for the competing risk of death (6.2%, 95% CI 4.8%-7.9%) and in a landmark analysis excluding the first 2 weeks after the index stroke and only including patients without permanent study drug discontinuation since then (6.8%, 95% CI 4.6%-8.9%). Conclusion Patients with AF and ischemic stroke while on oral anticoagulation are at increased risk of recurrent ischemic stroke and death. These patients currently have an unmet medical need. Key Question What is the risk of recurrent ischemic stroke and other outcomes in patients with atrial fibrillation who suffer an ischemic stroke while on warfarin or a direct oral anticoagulant? Key Finding In this COMBINE AF analysis of five randomized trials, the risk of ischemic stroke after a

Published
2023
Full Text
View/download PDF

36. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a <scp>post‐hoc</scp> analysis of the <scp>ATHENA</scp> trial

Author

Vaduganathan, Muthiah, Piccini, Jonathan P, Camm, A John, Crijns, Harry J G M, Anker, Stefan D, Butler, Javed, Stewart, John, Braceras, Rogelio, Albuquerque, Alessandro P A, Wieloch, Mattias, Hohnloser, Stefan H, MUMC+: MA Cardiologie (9), Cardiologie, and RS: Carim - H01 Clinical atrial fibrillation

Subjects
Aged, 80 and over, Heart Failure, Male, DEATH, Stroke Volume, Middle Aged, Prognosis, Atrial fibrillation, THERAPY, Ventricular Function, Left, Antiarrhythmic drugs, Ventricular Dysfunction, Left, Heart failure with preserved ejection fraction, Atrial Flutter, Humans, Female, Cardiology and Cardiovascular Medicine, Dronedarone, Aged
Abstract

AIMS: Limited therapeutic options are available for the management of atrial fibrillation/flutter (AF/AFL) with concomitant heart failure (HF) with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). Dronedarone reduces the risk of cardiovascular events in patients with AF, but sparse data are available examining its role in patients with AF complicated by HFpEF and HFmrEF.METHODS AND RESULTS: ATHENA was an international, multicentre trial that randomized 4628 patients with paroxysmal or persistent AF/AFL and cardiovascular risk factors to dronedarone 400 mg twice daily versus placebo. We evaluated patients with (i) symptomatic HFpEF and HFmrEF (defined as left ventricular ejection fraction [LVEF] >40%, evidence of structural heart disease, and New York Heart Association class II/III or diuretic use), (ii) HF with reduced ejection fraction (HFrEF) or left ventricular dysfunction (LVEF ≤40%), and (iii) those without HF. We assessed effects of dronedarone versus placebo on death or cardiovascular hospitalization (primary endpoint), other key efficacy endpoints, and safety. Overall, 534 (12%) had HFpEF or HFmrEF, 422 (9%) had HFrEF or left ventricular dysfunction, and 3672 (79%) did not have HF. Patients with HFpEF and HFmrEF had a mean age of 73 ± 9 years, 37% were women, and had a mean LVEF of 57 ± 9%. Over a mean follow-up of 21 ± 5 months, dronedarone consistently reduced risk of death or cardiovascular hospitalization (hazard ratio 0.76; 95% confidence interval 0.69-0.84) without heterogeneity based on HF status (pinteraction >0.10). This risk reduction in the primary endpoint was consistent across the range of LVEF (as a continuous function) in HF without heterogeneity (pinteraction = 0.71). Rates of death, cardiovascular hospitalization, and HF hospitalization each directionally favoured dronedarone versus placebo in HFpEF and HFmrEF, but these treatment effects were not statistically significant in this subgroup.CONCLUSIONS: Dronedarone is associated with reduced cardiovascular events in patients with paroxysmal or persistent AF/AFL and HF across the spectrum of LVEF, including among those with HFpEF and HFmrEF. These data support a rationale for a future dedicated and powered clinical trial to affirm the net clinical benefit of dronedarone in this population.

Published
2022

39. Contributors

Author

Aagaard, Philip, primary, Abrams, Dominic James, additional, Abriel, Hugues, additional, Adkisson, Wayne O., additional, Agullo-Pascual, Esperanza, additional, Alvarado, Francisco J., additional, Amin, Ahmad S., additional, Antzelevitch, Charles, additional, Anumonwo, Justus M.B., additional, Armaganijan, Luciana, additional, Arya, Arash, additional, Asirvatham, Samuel, additional, Atienza, Felipe, additional, Backx, Peter H., additional, Ballou, Lisa M., additional, Balse, Elise, additional, Balulad, Sujata, additional, Barbuti, Andrea, additional, Bardy, Gust H., additional, Bassil, Guillaume, additional, Benditt, David G., additional, Berenfeld, Omer, additional, Bers, Donald M., additional, Binah, Ofer, additional, Bogun, Frank, additional, Bongianino, Rossana, additional, Boyle, Noel G., additional, Boyle, Patrick M., additional, Breithardt, Günter, additional, Brini, Marisa, additional, Brink, Peter R., additional, Brugada, Pedro, additional, Buch, Eric, additional, Bukauskas, Feliksas F., additional, Calkins, Hugh, additional, Callans, David J., additional, Caples, Sean M., additional, Carafoli, Ernesto, additional, Catterall, William A., additional, Cerrone, Marina, additional, Chaumeil, Arnaud, additional, Chen, Caressa, additional, Chen, Lan S., additional, Chen, Peng-Sheng, additional, Cheng, Jianding, additional, Chiamvimonvat, Nipavan, additional, Christini, David J., additional, Chugh, Aman, additional, Climent, Andreu M., additional, Cohen, Ira S., additional, Connolly, Stuart J., additional, Cooper, Lebron, additional, Crespo, Eric M., additional, Crotti, Lia, additional, Csepe, Thomas A., additional, Cuoco, Frank, additional, Curtis, Anne B., additional, Damiano, Ralph J., additional, Darbar, Dawood, additional, Das, Mithilesh K., additional, d’Avila, Andre, additional, Delmar, Mario, additional, Delpón, Eva, additional, Denegri, Marco, additional, Denis, Arnaud, additional, Derval, Nicolas, additional, Deschênes, Isabelle, additional, Deshmukh, Abhishek, additional, Di Biase, Luigi, additional, Dickfeld, Timm M., additional, Dierckx, Hans, additional, Dinov, Borislav, additional, Dixit, Sanjay, additional, Dobrev, Dobromir, additional, Dubois, Remi, additional, Eckardt, Lars, additional, Edwards, Andrew G., additional, Ellenbogen, Kenneth A., additional, Ellinor, Patrick T., additional, Estes, N.A. Mark, additional, Fabritz, Larissa, additional, Fedorov, Vadim V., additional, Fernandez, Antonio B., additional, Teijeira Fernández, Elvis, additional, Filgueiras-Rama, David, additional, Fishbein, Michael C., additional, Fishman, Glenn I., additional, Frankel, David S., additional, Friedman, Paul, additional, Frontera, Antonio, additional, Gami, Apoor S., additional, Garabelli, Paul, additional, George, Alfred L., additional, Gerstenfeld, Edward P., additional, Gizurarson, Sigfus, additional, Gold, Michael R., additional, Goldberger, Jeffrey J., additional, Grace, Andrew, additional, Grassi, Guido, additional, Greenfield, Ruth Ann, additional, Gross, Wendy L., additional, Grubb, Blair P., additional, Guillem, María S., additional, Györke, Sándor, additional, Haïssaguerre, Michel, additional, Hake, Johan, additional, Halperin, Henry R., additional, Hansen, Brian J., additional, Hatem, Stéphane, additional, Hayes, David L., additional, Heijman, Jordi, additional, Herron, Todd J., additional, Hindricks, Gerhard, additional, Hocini, Mélèze, additional, Hohnloser, Stefan H., additional, Holmes, David R., additional, Hoshijima, Masahiko, additional, Hund, Thomas J., additional, Hutchinson, Mathew D., additional, Ilkhanoff, Leonard, additional, Ingles, Jodie, additional, Ip, James E., additional, Jackman, Warren M., additional, Jackson, Nicholas, additional, Jaïs, Pierre, additional, Jalife, José, additional, Jhun, Bong Sook, additional, John, Roy M., additional, Jongbloed, Monique, additional, Jordaens, Luc, additional, Kalman, Jonathan M., additional, Kamp, Timothy J., additional, Kanj, Mohamed H., additional, Kapa, Suraj, additional, Karabin, Beverly, additional, Karakikes, Ioannis, additional, Katritsis, Demosthenes G., additional, Kaur, Kuljeet, additional, Kirchhof, Paulus, additional, Kléber, André G., additional, Klein, George J., additional, Kohl, Peter, additional, Koneru, Jayanthi N., additional, Koruth, Jacob S., additional, Krahn, Andrew D., additional, Krogh-Madsen, Trine, additional, Kuck, Karl Heinz, additional, Kumar, Saurabh, additional, Kushnir, Alexander, additional, Lakdawala, Neal K., additional, Laksman, Zachary W.M., additional, Latchamsetty, Rakesh, additional, Lau, Dennis H., additional, Lerman, Bruce B., additional, Lin, Richard Z., additional, Lin, Shien-Fong, additional, Link, Mark S., additional, Liu, Bin, additional, Liu, Christopher F., additional, Lockwood, Deborah J., additional, Lopatin, Anatoli N., additional, Lubitz, Steven A., additional, Mahajan, Rajiv, additional, Makielski, Jonathan C., additional, Malik, Marek, additional, Marchlinski, Francis E., additional, Markowitz, Steven M., additional, Maron, Barry J., additional, Maron, Martin S., additional, Marx, Steven O., additional, Massé, Stéphane, additional, McCulloch, Andrew D., additional, McKelvie-Sebileau, Pippa, additional, Melby, Spencer J., additional, Metzner, Andreas, additional, Michailova, Anushka P., additional, Michaud, Gregory F., additional, Miller, John M., additional, Mishra, Jyotsna, additional, Mitrani, Raul D., additional, Mohler, Peter J., additional, Morady, Fred, additional, Myerburg, Robert J., additional, Nakagawa, Hiroshi, additional, Nalliah, Chrishan Joseph, additional, Nanthakumar, Kumaraswamy, additional, Napolitano, Carlo, additional, Narayan, Sanjiv M., additional, Natale, Andrea, additional, Nattel, Stanley, additional, Nazarian, Saman, additional, Nguyen, Thao P., additional, Nogami, Akihiko, additional, Noujaim, Sami F., additional, Nubret Le Coniat, Karine, additional, Olshansky, Brian, additional, O-Uchi, Jin, additional, Oudit, Gavin Y., additional, Ouyang, Feifan, additional, Ozcan, Cevher, additional, Packer, Douglas L., additional, Pandit, Sandeep V., additional, Panfilov, Alexander V., additional, Park, David S., additional, Patocskai, Bence, additional, Pauza, Dainius H., additional, Pauziene, Neringa, additional, Piccini, Jonathan P., additional, Pitt, Geoffrey S., additional, Po, Sunny S., additional, Prasad, Abhiram, additional, Priori, Silvia G., additional, Radwański, Przemysław B., additional, Rappel, Wouter-Jan, additional, Reiser, Michelle, additional, Restrepo, Alejandro Jimenez, additional, Robinson, Richard B., additional, Roden, Dan M., additional, Rosen, Michael R., additional, Rosso, Raphael, additional, Rudy, Yoram, additional, Rysevaite-Kyguoliene, Kristina, additional, Sabbah, Hani N., additional, Sacher, Frederic, additional, Sachse, Frank B., additional, Saguner, Ardan M., additional, Sanders, Prashanthan, additional, Sanguinetti, Michael C., additional, Santangeli, Pasquale, additional, Sarraf, Mohammad, additional, Satin, Jonathan, additional, Schalij, Martin Jan, additional, Scherlag, Benjamin J., additional, Schill, Matthew R., additional, Schleifer, J. William, additional, Schuessler, Richard B., additional, Schwartz, Peter J., additional, Seeger, Timon, additional, Semsarian, Christopher, additional, Seravalle, Gino, additional, Shah, Ashok J., additional, Shaw, Robin M., additional, Shen, Mark J., additional, Shen, Win–Kuang, additional, Sheu, Shey-Shing, additional, Shivkumar, Kalyanam, additional, Silva, Jennifer N.A., additional, Skanes, Allan C., additional, Soejima, Kyoko, additional, Somers, Virend K., additional, Sorajja, Dan, additional, Stavrakis, Stavros, additional, Steinberg, Christian, additional, Stevenson, Lynne Warner, additional, Stevenson, William G., additional, Sweeney, Michael O., additional, Swerdlow, Charles, additional, Takigawa, Masateru, additional, Tamargo, Juan, additional, Tandri, Harikrishna, additional, Tedrow, Usha B., additional, Thompson, Nathaniel, additional, Thompson, Paul D., additional, Tomaselli, Gordon F., additional, Towbin, Jeffrey A., additional, Trayanova, Natalia A., additional, Tristani-Firouzi, Martin, additional, Tseng, Zian H., additional, Ueda, Akiko, additional, Valdivia, Héctor H., additional, Valiunas, Virginijus, additional, van der Werf, Christian, additional, Van Hare, George F., additional, Vidmar, David, additional, Viskin, Sami, additional, Voigt, Niels, additional, Walsh, Edward P., additional, Wang, Paul J., additional, Wehrens, Xander H.T., additional, Weiss, Mark S., additional, Wilde, Arthur A.M., additional, Wilkoff, Bruce L., additional, Woo, Y. Joseph, additional, Wu, Joseph C., additional, Yee, Raymond, additional, Zaman, Junaid A.B., additional, Zarzoso, Manuel, additional, Zeitler, Emily P., additional, Zeppenfeld, Katja, additional, Zghaib, Tarek, additional, Zhang, Xiao-Dong, additional, and Zipes, Douglas P., additional

Published
2018
Full Text
View/download PDF

41. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)

Author

Healey, Jeff S, Hohnloser, Stefan H, Glikson, Michael, Neuzner, Jorg, Mabo, Phillipe, Vinolas, Xavier, Kautzner, Josef, O'Hara, Gilles, VanErven, Lieselot, Gadler, Fredrik, Pogue, Janice, Appl, Ursula, Gilkerson, Jim, Pochet, Thierry, Stein, Kenneth M, Merkely, Bela, Chrolavicius, Susan, Meeks, Brandi, Foldesi, Csaba, Thibault, Bernard, and Connolly, Stuart J

Published
2015
Full Text
View/download PDF

42. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P, Hong, Hwanhee, Connolly, Stuart J, Eikelboom, John, Giugliano, Robert P, Morrow, David A, Patel, Manesh R, Wallentin, Lars, Alexander, John H, Bahit, M Cecilia, Benz, Alexander P, Bohula, Erin A, Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, Fox, Keith Aa, Gencer, Baris, Halperin, Jonathan L, Hijazi, Ziad, Hohnloser, Stefan H, Hua, Kaiyuan, Hylek, Elaine, Kato, Eri Toda, Kuder, Julia, Lopes, Renato D, Mahaffey, Kenneth W, Oldgren, Jonas, Piccini, Jonathan P, Ruff, Christian T, Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B

Subjects
Male, Network Meta-Analysis, Age Factors, Administration, Oral, Anticoagulants, Sex Factors, Risk Factors, Physiology (medical), Humans, Female, Warfarin, 610 Medicine & health, Cardiology and Cardiovascular Medicine, 360 Social problems & social services, Aged, Randomized Controlled Trials as Topic
Abstract

Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.

Published
2023

49. Case 148

Author

Ehrlich, Joachim, Hohnloser, Stefan H., Natale, Andrea, editor, Al-Ahmad, Amin, editor, Wang, Paul J., editor, and DiMarco, John, editor

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results